Intraday trading saw Novo Nordisk shares plunge as much as 20%, the biggest drop since July 2021, including a trading halt and post-halt 5% slide, before partial morning recoveries gave way to further afternoon declines. Board members and executives have continued share transfers and tax-covering sales under the long-term incentive programme amid high volatility.

Strong demand for GLP-1 products drove 2025 sales growth of about 10% and operating profit growth of 6%, with obesity care revenues surging from DKK 6 billion in 2019 to DKK 82 billion in 2025. The Wegovy pill launched to 170,000 users in its first month and injectable Ozempic volume offset lower realized prices, while Q4 revenues dipped 2% at constant exchange rates amid intensifying competition. Novo Nordisk plans an Ozempic pill launch in Q2 2026, maintains cost discipline and over DKK 67 billion in shareholder returns, but forecasts adjusted sales to decline 5–13% in 2026.

US government cost-cutting initiatives, including Trump administration most-favored-nation deals with five major drugmakers and a $50 cap for Medicare Part D GLP-1 drugs, have imposed deep price concessions and heightened regulatory scrutiny on weight-loss therapies. Meanwhile, unauthorized compounding and copycat semaglutide offerings have triggered FDA crackdowns and prolific legal actions by Novo Nordisk to defend its intellectual property and branded pricing. Alongside looming patent expirations in key markets and potential rule changes for compounding practices, these external constraints and legal frameworks are reshaping the competitive structure and pricing power in the GLP-1 obesity treatment market.

Investor confidence plunged after guidance forecasting a 5%–13% sales decline in 2026 and intensifying price wars, prompting broad pessimism and steep valuation reappraisals. At the same time, narratives around strong early uptake of the oral Wegovy pill and anticipated FDA crackdowns on copycats have rallied select bulls and spurred notable stake increases.